Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hormone-dependent Advanced Prostate Carcinoma (Stage D) Age: Adult Condition: Loading dose |
Dose: Subcutaneous solution – 240 mg Frequency: Given as 2 separate injections of 120 mg Note: As 40 mg/mL solution. Doses are administered in the abdominal area. |
|
Indication: Hormone-dependent Advanced Prostate Carcinoma (Stage D) Age: Adult Condition: Maintenance |
Dose: Subcutaneous solution – 80 mg Frequency: Once every 28 days Note: As 20 mg/mL solution. Starting 28 days after the initial dose. Doses are administered in the abdominal area. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: NO_HEADER – No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment (greater than 50 mL/min) |
Dose: Not specified Note: Dose adjustment not necessary |
|
Condition: Renal Impairment (less than 50 mL/min) |
Dose: Not specified Note: Use caution |
Administration
- For subcutaneous injection only
- Given by healthcare professional
Side Effect
- Hot flashes (26%)
- Injection site erythema (17%)
- Injection site pain (28%)
- Weight gain (11%)
- Elevated liver enzymes (10%)
- Arthralgia
- Back pain
- Fatigue
- HTN
- Injection site induration/swelling
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Class IA (e.g. disopyramide) or class III (e.g. amiodarone) Antiarrhythmics (Amiodarone, Flecainide, Propafenone, Quinidine, Disopyramide, Procainamide), Antipsychotics (Haloperidol, Risperidone, Quetiapine, Olanzapine, Clozapine, Aripiprazole), methadone, moxifloxacin
|
Increased risk of QT prolongation
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
No specific contraindications listed
|
Monitor for general reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
This medicinal product does not require any special storage conditions. Chemical and physical in-use stability has been demonstrated for 2 hours at 25°C. From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.